U.S., Oct. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07859202) titled 'The Purpose of This Study is to Evaluate the Efficacy and Safety of W2505.' on Sept. 29.

Brief Summary: The purpose of this study is to evaluate the efficacy and safety of W2505.

Study Start Date: Sept., 2026

Study Type: INTERVENTIONAL

Condition: Erectile Dysfunctions

Intervention: DRUG: W2505

PO, Once daily(QD), 12 weeks

DRUG: W2505-P1

PO, Once daily(QD), 12 weeks

DRUG: W2505-R

PO, Once daily(QD), 12 weeks

DRUG: W2505-P2

PO, Once daily(QD), 12 weeks

Recruitment Status: NOT_YET_RECRUITING

Sponsor: GL Pharm Tech Corporation

Disclaimer: Curated by HT Syndication....